Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neumentix
- Development stage
- Phase 3
- Lead developer
- Kemin Industries
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Neumentix (K110-42) is a proprietary botanical extract derived from specialized, non-GMO lines of spearmint (*Mentha spicata*) developed by Kemin Industries. It is a complex mixture containing over 50 phenolic constituents, including rosmarinic acid, and is primarily marketed as a dietary supplement for cognitive health. The extract has been clinically studied for its ability to improve working memory and focus in adults with age-associated memory impairment. Currently, it is being evaluated in a Phase 3 clinical trial led by Mansoura University to assess its efficacy in enhancing cognitive functions in children aged 4 to 8 years with Down syndrome. Its mechanism of action is believed to involve antioxidant and neuroprotective properties that support neuronal health and neurotransmitter levels, although its specific molecular targets are not fully characterized.
- Brand names
- Neumentix
- Other names
- Phenolic complex K110-42Spearmint phenolic complex
Beyond the preview
Go deeper on Neumentix.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neumentix.